$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000162828020004221 Filed on March 27, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.280M	$6.080M	$2.150M
YoY Change	-22.18%	-40.39%	-19.48%
% of Gross Profit
Research & Development	$1.652M	$8.086M	$3.330M
YoY Change	-56.44%	-21.66%	-1.19%
% of Gross Profit
Depreciation & Amortization	$18.00K	$100.0K	$90.00K
YoY Change	23.25%	101.52%	-74.29%
% of Gross Profit
Operating Expenses	$3.929M	$14.16M	$5.470M
YoY Change	-18.84%	-12.25%	-9.29%
Operating Profit	-$3.929M	-$14.16M
YoY Change	-18.84%	-12.25%
Interest Expense	$15.00K	$1.768M	$7.420M
YoY Change	-97.84%	-52.86%	-1039.24%
% of Operating Profit
Other Income/Expense, Net	-$15.00K	-$6.080M	-$40.00K
YoY Change	-98.98%	192.43%	-233.33%
Pretax Income	-$3.940M	-$20.20M	-$820.0K
YoY Change	-58.17%	137.56%	-87.94%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.944M	-$20.24M	-$820.0K
YoY Change	-37.52%	11.23%	-87.94%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.46
Diluted Earnings Per Share	-$74.86K	-$1.46	-$828.3K
COMMON SHARES
Basic Shares Outstanding	52.63M shares	13.89M shares
Diluted Shares Outstanding		13.89M shares

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.190M	$7.440M	$15.54M
YoY Change	-56.78%	-52.12%	94.71%
Cash & Equivalents	$3.193M	$7.440M	$1.628M
Short-Term Investments			$0.00
Other Short-Term Assets	$8.170M	$8.320M	$172.0K
YoY Change	975.0%	867.44%	40.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$11.36M	$15.77M	$1.942M
YoY Change	39.59%	-3.84%	-76.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$249.0K	$220.0K	$245.8K
YoY Change	84.44%	57.14%	-90.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$551.2K	$820.0K	$116.3K
YoY Change	-91.42%	-7.87%	-16.91%
Total Long-Term Assets	$951.3K	$1.040M	$512.6K
YoY Change	-85.8%	0.97%	-82.08%
TOTAL ASSETS
Total Short-Term Assets	$11.36M	$15.77M	$1.942M
Total Long-Term Assets	$951.3K	$1.040M	$512.6K
Total Assets	$12.31M	$16.81M	$2.454M
YoY Change	-17.01%	-3.56%	-77.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.548M	$1.900M	$3.278M
YoY Change	40.76%	19.5%	322.36%
Accrued Expenses	$1.384M	$2.440M	$1.403M
YoY Change	1297.63%	144.0%	-48.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$7.484M
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.315M	$4.540M	$14.11M
YoY Change	43.07%	58.19%	270.82%
LONG-TERM LIABILITIES
Long-Term Debt	$1.581M	$1.070M	$1.017M
YoY Change
Other Long-Term Liabilities	$3.940K	$170.0K	$37.46K
YoY Change	-99.98%	-98.87%	-99.8%
Total Long-Term Liabilities	$1.702M	$1.240M	$1.054M
YoY Change	-90.57%	-91.74%	-94.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.315M	$4.540M	$14.11M
Total Long-Term Liabilities	$1.702M	$1.240M	$1.054M
Total Liabilities	$5.017M	$5.790M	$15.16M
YoY Change	-75.37%	-67.64%	-32.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.40M		$31.24M
YoY Change	-75.51%		-115.0%
Common Stock	$527.5K		$215.9M
YoY Change	-99.76%		9.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$47.86K
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.297M	$11.02M	-$12.71M
YoY Change
Total Liabilities & Shareholders Equity	$12.31M	$16.81M	$2.454M
YoY Change	-17.01%	-3.56%	-77.76%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$3.944M	-$20.24M	-$820.0K
YoY Change	-37.52%	11.23%	-87.94%
Depreciation, Depletion And Amortization	$18.00K	$100.0K	$90.00K
YoY Change	23.25%	101.52%	-74.29%
Cash From Operating Activities	-$4.686M	-$16.89M	-$6.940M
YoY Change	75.69%	45.25%	60.65%
INVESTING ACTIVITIES
Capital Expenditures	$53.00K	$30.00K	-$70.00K
YoY Change	400.9%	-61.25%	-53.33%
Acquisitions
YoY Change
Other Investing Activities		-$2.330M	$0.00
YoY Change		-358.89%	-100.0%
Cash From Investing Activities	-$53.00K	-$2.357M	-$70.00K
YoY Change	400.9%	2944.67%	-109.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	-$1.135M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$488.0K	$25.07M	17.36M
YoY Change	-64.09%	248.89%	-11673.33%
NET CHANGE
Cash From Operating Activities	-$4.686M	-$16.89M	-6.940M
Cash From Investing Activities	-$53.00K	-$2.357M	-70.00K
Cash From Financing Activities	$488.0K	$25.07M	17.36M
Net Change In Cash	-$4.251M	$5.816M	10.35M
YoY Change	222.22%	-228.59%	-378.23%
FREE CASH FLOW
Cash From Operating Activities	-$4.686M	-$16.89M	-$6.940M
Capital Expenditures	$53.00K	$30.00K	-$70.00K
Free Cash Flow	-$4.739M	-$16.92M	-$6.870M
YoY Change	76.97%	44.54%	64.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019Q4	ocgn	Converted Additional Shares Threshold Release Trigger Period ConvertedAdditionalSharesThresholdReleaseTriggerPeriod	P3D
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-36751
CY2019	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern,
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Great Valley Parkway, Suite 160
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2019	dei	City Area Code CityAreaCode	484
CY2019	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2019	dei	Security12b Title Security12bTitle	Common Stock
CY2019	dei	Trading Symbol TradingSymbol	OCGN
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	18100000	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	52625228	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7444052	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1628136	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1322167	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	313499	USD
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	15766219	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1941635	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222464	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245788	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151016	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	150477	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	667747	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	116333	USD
CY2019Q4	us-gaap	Assets Assets	16807446	USD
CY2018Q4	us-gaap	Assets Assets	2454233	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1895613	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3277525	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1402750	USD
CY2018Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	7483847	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1741222	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	205991	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	204242	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4543959	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14109586	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1072123	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1016727	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9755	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37459	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1245076	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1054186	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5789035	USD
CY2018Q4	us-gaap	Liabilities Liabilities	15163772	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52746728	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4960552	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52625228	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4960552	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	527467	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	49606	USD
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2018Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	47864	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	451	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62018632	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18477598	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	51479824	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	31237194	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-12709539	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16807446	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2454233	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8085522	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10321397	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6077097	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5819111	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14162619	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	16140508	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-14162619	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-16140508	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187380	USD
CY2018	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1664689	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341136	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1214	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	19213	USD
CY2019	us-gaap	Interest Expense InterestExpense	1767836	USD
CY2018	us-gaap	Interest Expense InterestExpense	3750630	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-784873	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12428	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6080011	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2079156	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18219664	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-451	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11630543	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	451	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20243081	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18219213	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.67
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13893819	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4960552	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4434987	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	451	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1074687	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18219664	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-12709539	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13979788	USD
CY2019	ocgn	Stock Issued During Period Pre Merger Value StockIssuedDuringPeriodPreMergerValue	13150456	USD
CY2019	ocgn	Costs Related To Issuance Of Stock Under Reverse Asset Acquisition CostsRelatedToIssuanceOfStockUnderReverseAssetAcquisition	2600000	USD
CY2019	ocgn	Stock Issued During Period Value Reverse Asset Acquisition StockIssuedDuringPeriodValueReverseAssetAcquisition	3565788	USD
CY2018	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1664689	USD
CY2019	ocgn	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	11255740	USD
CY2019	ocgn	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	183034	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	47864	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-451	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884089	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20242630	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-20242630	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-18219664	USD
CY2019	us-gaap	Depreciation Depreciation	60608	USD
CY2018	us-gaap	Depreciation Depreciation	49623	USD
CY2019	ocgn	Non Cash Interest Expense NonCashInterestExpense	1733521	USD
CY2018	ocgn	Non Cash Interest Expense NonCashInterestExpense	3750630	USD
CY2019	ocgn	Noncash Lease Expense NoncashLeaseExpense	250361	USD
CY2018	ocgn	Noncash Lease Expense NoncashLeaseExpense	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187380	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884089	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1074687	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341136	USD
CY2018	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2019	us-gaap	Other Noncash Expense OtherNoncashExpense	4803	USD
CY2018	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1007367	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	201861	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1628621	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3633394	USD
CY2019	ocgn	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2018	ocgn	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	1540	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	227172	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	54203	USD
CY2019	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-249389	USD
CY2018	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16893281	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29446	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77414	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2327273	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2356719	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77414	USD
CY2019	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	22546353	USD
CY2018	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	47864	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	183034	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	5290000	USD
CY2018	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	63817	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	99202	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6800000	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7300400	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	103925	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	25866	USD
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11928	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25066455	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7184547	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	451	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5816455	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4522959	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1778613	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6301572	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1778613	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2017Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0	USD
CY2019	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	13979788	USD
CY2018	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2019	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	1150000	USD
CY2018	ocgn	Noncash Or Part Noncash Amount Of Deferred Transaction Cost NoncashOrPartNoncashAmountOfDeferredTransactionCost	0	USD
CY2019	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	470356	USD
CY2018	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	0	USD
CY2019	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	2252795	USD
CY2018	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The Company is located in Malvern, Pennsylvania.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen has a late-stage, Phase 3 program, OCU300, which has received Orphan Drug Designation ("ODD") from the U.S. Food and Drug Administration ("FDA"). OCU300 is a small molecule therapeutic currently in Phase 3 clinical development for patients with ocular redness and discomfort stemming from ocular graft-versus-host disease (“oGVHD”). Ocugen is the first and only company to receive ODD for the treatment of symptoms associated with oGVHD and is the only company conducting Phase 3 studies in this patient population. OCU300 is formulated using the Company’s proprietary nanoemulsion technology, OcuNanoE—Ocugen’s ONE Platform™ (“OcuNanoE™”).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is developing a modifier gene therapy platform for unmet medical needs in the area of retinal diseases, including inherited retinal diseases (“IRDs”). Ocugen’s modifier gene therapy platform is novel in that it targets nuclear hormone receptors (“NHRs”), which have the potential to restore homeostasis to the retina and may target multiple genes that are associated with a range of IRDs. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its targeting of NHRs, may impact multiple genes that are associated with a range of genetically diverse diseases. Ocugen’s first gene therapy candidate, OCU400, has received ODD from the FDA, for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">mutation-associated retinal diseases and centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases. Ocugen’s second gene therapy product candidate, OCU410, is targeted for dry age-related macular degeneration (“AMD”) and is currently in preclinical development. Currently, there are no FDA-approved therapies to treat this disease.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is also developing OCU200, a novel fusion protein for the treatment of wet AMD, diabetic retinopathy (“DR”) and diabetic macular edema (“DME”), which is in preclinical development. Ocugen expects to initiate a Phase 1/2 clinical trial for OCU200 within the next two years. Ocugen plans to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion (“RVO”) and myopic choroidal neovascularization (“mCNV”).</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, the Company completed its reverse merger with Ocugen, OpCo Inc. (formerly known as Ocugen, Inc. (“Former Ocugen”)) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, by and among Histogenics, Former Ocugen and Restore Merger Sub, Inc., a wholly owned subsidiary of Histogenics (“Merger Sub”), as amended (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Former Ocugen, with Former Ocugen surviving as a wholly owned subsidiary of Histogenics (the “Merger”). Immediately after completion of the Merger, Histogenics changed its name to Ocugen, Inc. and the business conducted by Ocugen, Inc. became the business conducted by Former Ocugen. Former Ocugen is deemed to be the accounting acquirer. Accordingly, the historical financial statements of Former Ocugen became the Company’s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the ‘‘Reverse Stock Split’’). Under the terms of the Merger Agreement, the Company issued common stock to Former Ocugen’s stockholders at an exchange rate of 0.4794 shares of common stock, after taking into account the Reverse Stock Split, for each share of Former Ocugen’s common stock outstanding immediately prior to the Merger.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The capital structure, including the number of shares of common stock issued appearing in the consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and debt. The Company incurred net losses of approximately $20.2 million and $18.2 million for the year ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $51.5 million as of December 31, 2019. As of December 31, 2019, the Company had cash, cash equivalents and restricted cash totaling $7.6 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company’s products, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these audited consolidated financial statements are issued. The audited consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div>
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20200000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18200000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	51500000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7600000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements, warrants, and embedded conversion features on the convertible notes.</span></div>
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000.0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7444052	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1628136	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151016	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	150477	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1778613	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q4	ocgn	Converted Additional Shares Threshold Release Trigger ConvertedAdditionalSharesThresholdReleaseTrigger	0.80
CY2019Q4	ocgn	Asset Purchase Agreement Cash Consideration AssetPurchaseAgreementCashConsideration	8500000	USD
CY2018	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1664689	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20242630	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20242630	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18219664	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18219664	USD
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13893819	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4960552	shares
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.46
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.67
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10375137	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1502772	shares
CY2019Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	271322	USD
CY2018Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	705436	USD
CY2019Q4	ocgn	Accounts Payable Clinical AccountsPayableClinical	421788	USD
CY2018Q4	ocgn	Accounts Payable Clinical AccountsPayableClinical	469473	USD
CY2019Q4	ocgn	Accounts Payable Consulting AccountsPayableConsulting	98245	USD
CY2018Q4	ocgn	Accounts Payable Consulting AccountsPayableConsulting	86619	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	624420	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	819323	USD
CY2018	ocgn	Embedded Derivative Fair Value Of Embedded Derivative Liability At Issuance EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance	3405911	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	123372	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15400	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34947	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2450	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1402750	USD
CY2019	us-gaap	Debt Instrument Term DebtInstrumentTerm	P18M
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	344574	USD
CY2018Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1741222	USD
CY2019	ocgn	Embedded Derivative Fair Value Of Embedded Derivative Liability At Issuance EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiabilityAtIssuance	567661	USD
CY2019	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	1319400	USD
CY2019	ocgn	Embedded Derivative Conversion And Extinguishment Of Debt EmbeddedDerivativeConversionAndExtinguishmentOfDebt	3628283	USD
CY2019Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0	USD
CY2019Q2	ocgn	Common Stock Shares Agreed To Be Sold Stock Subscription Agreement CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement	100000	shares
CY2019Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1000000.0	USD
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.41
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	13000000.0	USD
CY2019Q2	ocgn	Common Stock Shares Agreed To Be Sold Stock Subscription Agreement CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement	100000	shares
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.41
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	900000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884089	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	250361	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	79700	USD
CY2019	us-gaap	Lease Cost LeaseCost	330061	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1074687	USD
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	USD
CY2019Q4	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	segment
CY2019	ocgn	Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Shares To Be Issue Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage	0.040
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.84
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.97
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000.0	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	335508	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	191890	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	160909	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11354	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	364153	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28645	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	335508	USD
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2019Q4	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.076
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	23856	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	9941	USD
CY2019Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1851	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	33797	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	31946	USD
CY2019Q4	ocgn	Pre Merger Financing Warrants Block Provisions Exercise Restriction Lower Percentage Of Common Stock PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionLowerPercentageOfCommonStock	0.0499
CY2019Q4	ocgn	Pre Merger Financing Warrants Block Provisions Exercise Restriction Higher Percentage Of Common Stock PreMergerFinancingWarrantsBlockProvisionsExerciseRestrictionHigherPercentageOfCommonStock	0.0999
	ocgn	Percentage Of Amount On Market Value For Failure To Issue Common Stock On Pre Merger Financing Warrants PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants	0.020
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2019	ocgn	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	49385964	shares
CY2019	ocgn	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	40612036	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8773928	shares
CY2017Q4	ocgn	Number Of Former Employees With Warrants NumberOfFormerEmployeesWithWarrants	2	segment
CY2018Q4	ocgn	Deferred Tax Assets Convertible Debt DeferredTaxAssetsConvertibleDebt	498236	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20200000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-18200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31575288	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6864360	USD
CY2019Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298052	USD
CY2018Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2019Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11234751	USD
CY2018Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	166611	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	35645	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	555352	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	121694	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1123100	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	993234	USD
CY2019Q4	ocgn	Deferred Tax Assets Convertible Debt DeferredTaxAssetsConvertibleDebt	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1926677	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	548399	USD
CY2019Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	96895	USD
CY2018Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53976726	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9061568	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	53877168	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9061568	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	99558	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	99558	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	44800000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.076
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.021
CY2019	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.081
CY2018	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.029
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.243
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.299
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	303050	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303050	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	USD

Files In Submission

Name	View Source	Status
0001628280-20-004221-index-headers.html	Edgar Link	pending
0001628280-20-004221-index.html	Edgar Link	pending
0001628280-20-004221.txt	Edgar Link	pending
0001628280-20-004221-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20191231.htm	Edgar Link	pending
ocgn-20191231.xsd	Edgar Link	pending
ocgn-20191231x10kxex10.htm	Edgar Link	pending
ocgn-20191231x10kxex101.htm	Edgar Link	pending
ocgn-20191231x10kxex211.htm	Edgar Link	pending
ocgn-20191231x10kxex231.htm	Edgar Link	pending
ocgn-20191231x10kxex311.htm	Edgar Link	pending
ocgn-20191231x10kxex312.htm	Edgar Link	pending
ocgn-20191231x10kxex321.htm	Edgar Link	pending
ocgn-20191231x10kxex41.htm	Edgar Link	pending
ocgn-20191231_cal.xml	Edgar Link	unprocessable
ocgn-20191231_def.xml	Edgar Link	unprocessable
ocgn-20191231_g1.jpg	Edgar Link	pending
ocgn-20191231_g10.jpg	Edgar Link	pending
ocgn-20191231_g11.jpg	Edgar Link	pending
ocgn-20191231_g12.jpg	Edgar Link	pending
ocgn-20191231_g13.jpg	Edgar Link	pending
ocgn-20191231_g14.jpg	Edgar Link	pending
ocgn-20191231_g15.jpg	Edgar Link	pending
ocgn-20191231_g2.jpg	Edgar Link	pending
ocgn-20191231_g3.jpg	Edgar Link	pending
ocgn-20191231_g4.jpg	Edgar Link	pending
ocgn-20191231_g5.jpg	Edgar Link	pending
ocgn-20191231_g6.jpg	Edgar Link	pending
ocgn-20191231_g7.jpg	Edgar Link	pending
ocgn-20191231_g8.jpg	Edgar Link	pending
ocgn-20191231_g9.jpg	Edgar Link	pending
ocgn-20191231_htm.xml	Edgar Link	completed
ocgn-20191231_lab.xml	Edgar Link	unprocessable
ocgn-20191231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2020 Q1 Form 10-K Financial Statement

#000162828020004221 Filed on March 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2020 Q1 Form 10-K Financial Statement

#000162828020004221 Filed on March 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn